An interventional study of Subject management guided by NephroCheck® test and Standard of Care in Sepsis, Acute Kidney Injury and Septic Shock, sponsored by BioMérieux. Terminated at 12 sites in 4 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by BioMérieux · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Shock, Septic with a site in France — 45 open to participants now, 50 under way, 7 of them phase 3. Shock, Septic · France.
Among the 184 studies in Shock, Septic with a site in France, this one is the 99th largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2021, is one of 52 with no phase, and was the 114th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →45 of the 184 studies in Shock, Septic with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre National de la Recherche Scientifique, France · Sites in France
Ages 18–49 · Women only · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 19 · Phase 3 32 · Phase 4 9
First in 1997; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 120 across the 105 interventional studies, 100 across the 79 observational. Of the 108 that completed or were terminated, 6 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 184 have an industry lead sponsor. The 10 most frequent:
BioMérieux is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
BioMérieux has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
13 of the studies in Shock, Septic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04748796Phase 3Centre Hospitalier Universitaire, AmiensComparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility | 2027-06 |
| NCT07085624Centre Hospitalier Universitaire de Saint EtienneEarly Optimization of Ceftazidime Regimen in Critical Care | 2026-11 |
| NCT04067674Hospices Civils de LyonSeptic Shock-induced Immunosuppression | 2026-11-21 |
| NCT07354568Centre Hospitalier Universitaire, AmiensPrognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock | 2027-01-01 |
| NCT07199998Centre National de la Recherche Scientifique, FranceImpact of Internal Menstrual Protections on Immunity and Vaginal Microbiota | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 184 studies in Shock, Septic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Biomarkers that provide an early indicator of kidney stress could be useful in clinical practice to detect silent episodes of acute kidney injury (AKI) or for early identification of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators of AKI. The NephroCheck® test is a commercially available test that uses these biomarkers, and this study assesses the use of these in reducing negative clinical outcomes for patients with sepsis-associated AKI. The study will enroll subjects diagnosed with sepsis, including septic shock, who will be randomly assigned to either receive NephroCheck®-guided kidney-sparing and fast-tracking interventions; or to receive current Standard of Care assessment and treatment.
NOTE: Participants are no longer being recruited to this study.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's enrollment of 19 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →BioMérieux is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects already included in an observational study can be co-enrolled in LAPIS. Subjects already included in an interventional study may be enrolled with pre-approval of the sponsor according to the following rules:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Subject management guided by NephroCheck® test
Standard of Care assessment and treatment
Other: Standard of Care
NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
Standard of Care patient management
Number of deaths, dialysis or progression of AKI
Measured by composite number of deaths, dialysis or progression of AKI. Dialysis defined as any form of renal replacement therapy (RRT); progression of AKI defined as Stage 0 to 2/3 or Stage 1 to 3.
Time frame: Enrollment to 72 hours
Number of participants with progression of AKI
Progression of AKI (Acute Kidney Injury) to Stage 2 or 3 during the time frame. Measured independently.
Time frame: Enrollment to 48 and 72 hours
Number of deaths
Number of deaths. Measured independently.
Time frame: Enrollment to 48 and 72 hours
Number of participants receiving dialysis
Dialysis defined as any form of renal replacement therapy (RRT). Measured independently.
Time frame: Enrollment to 48 and 72 hours
Number participants at Stage 2 or 3 AKI
Defined as highest stage of AKI during the time frame
Time frame: Enrollment to 72 hours
ICU length of stay
Time frame: Enrollment to hospital discharge or Day 60, whichever is sooner
Ran from Jan 2021 to primary completion in Feb 2022, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioMérieux